Donal O'Connor - 19 May 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
19 May 2025
Transactions value $
$0
Form type
4
Filing time
21 May 2025, 19:17:55 UTC
Previous filing
16 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
O'Connor Donal Director C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Brett A. Grimaud, Attorney-in-Fact 21 May 2025 0001625377

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +10,649 +17% $0 74,204 19 May 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Award $0 +24,258 $0 24,258 19 May 2025 Ordinary Shares 24,258 $9.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.